Repair Biotechnologies Receives Orphan Drug Designation from the FDA for the Treatment of Homozygous Familial Hypercholesterolemia
Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board
Repair Biotechnologies Announces Positive Pre-IND Meeting with FDA for REP-0003 to Treat Homozygous Familial Hypercholesterolemia
Repair Biotechnologies Receives Orphan Drug Designation from the FDA for the Treatment of Homozygous Familial Hypercholesterolemia Read more
Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board Read more
Repair Biotechnologies Announces Positive Pre-IND Meeting with FDA for REP-0003 to Treat Homozygous Familial Hypercholesterolemia Read more
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis Read more
Repair Biotechnologies Announces Appointment of Noted Cardiologists to Scientific Advisory Board Read more
